You are here

Journal of Psoriasis and Psoriatic Arthritis®

Published in Association with National Psoriasis Foundation
Other Titles in:
Dermatology | Rheumatology

eISSN: 24755311 | ISSN: 24755303 | Current volume: 9 | Current issue: 1 Frequency: Quarterly
The Journal of Psoriasis and Psoriatic Arthritis (JPPA) is a peer-reviewed specialty journal of the National Psoriasis Foundation for its professional members and for dermatology and rheumatology specialists and community. The purpose of the journal is to provide the latest research and practical treatment information about psoriasis, psoriatic arthritis and related comorbidities and conditions in a concise and easy-to-read format. JPPA bases its policies on the guidelines set forth by the International Committee of Medical Journal Editors. Earn AMA PRA Category 1 Credit(s)™ for selected articles.

This journal is a member of the Committee on Publication Ethics (COPE).

The Journal of Psoriasis and Psoriatic Arthritis (JPPA) is a quarterly, peer-reviewed, specialty journal published by the National Psoriasis Foundation (NPF). The journal disseminates the latest clinical, translational, and basic research and practical treatment information about psoriasis, psoriatic arthritis, as well as related comorbidities and conditions. The goal of the JPPA is to provide readers with knowledge that advances their expertise, a goal accomplished by publishing evidence-based research.

Article Types:
JPPA publishes original research, review articles, case studies, commentary, and brief reports on all aspects of psoriatic disease including basic research, evaluation and diagnosis, heredity, pharmacotherapy, and symptom management.

Diversity, Equity, and Inclusion:
Psoriatic disease doesn’t discriminate. NPF advocates for improved access to care and meaningful access to treatments for all. JPPA is passionate about supporting diversity, equity, and inclusion in wider society through our publishing activities, which include ensuring diversity (ethnic and gender) in our editorial board, peer reviewers, and author base.

Bruce Strober, MD, PhD Clinical Professor of Dermatology, Yale University, New Haven, CT; Central Connecticut Dermatology, Cromwell, CT, USA
Founding Editors
Alice B. Gottlieb, MD, PhD Icahn School of Medicine at Mount Sinai, New York, NY, USA
John Y. M. Koo, MD University of California-San Francisco Medical Center, San Francisco, CA, USA
Mark Lebwohl, MD Icahn School of Medicine at Mount Sinai, New York, NY, USA
Senior Editors
April Armstrong, MD, MPH Keck School of Medicine, Clinical and Translational Science Institute, University of Southern California, Los Angeles, CA, USA
Andy Blauvelt, MD, MBA Oregon Medical Research Center, Portland, OR, USA
Megan H. Noe, MD, MPH, MSCE Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Mona Shahriari, MD, FAAD Yale University, New Haven, CT; Central CT Dermatology, Cromwell, CT, USA
Associate Editors
Lakshi Aldredge, MSN, ANP-C VA Portland Health Care System, Portland, OR, USA
Herve Bachelez, MD, PhD Hôpital Saint-Louis Sorbonne Paris Cité, Université Paris Diderot, Paris, France
Jerry Bagel, MD Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA
Luca Bianchi, MD University of Rome Tor Vergata, Rome, Italy
David R. Bickers, MD Columbia University Medical Center, New York, NY, USA
Robert Bissonnette, MD University of Montreal Hospital Centre, Montreal, Canada
Erin Boh, MD, PhD Tulane University School of Medicine, New Orleans, LA, USA
Anne M. Bowcock, PhD Icahn School of Medicine at Mount Sinai, New York, NY, USA
Jeffrey P. Callen, MD University of Louisville, Louisville, KY, USA
Vinod Chandran, MBBS, MD, DM, PhD University of Toronto, Department of Medicine, Division of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada
Robin Christensen, BSc, MSc, PhD The Parker Institute, Copenhagen, Denmark
Kelly Cordoro, MD University of California, San Francisco, CA, USA
Jeffrey Crowley, MD Bakersfield Dermatology, Bakersfield, CA, USA
Kristina Callis Duffin, MD The University of Utah, Salt Lake City, UT, USA
Lawrence Eichenfield, MD University of California, San Diego, CA, USA
Charles N. Ellis, MD University of Michigan Medical School, Ann Arbor, MI, USA
Steven Feldman, MD, PhD Wake Forest Baptist Medical Center, Winston-Salem, NC, USA
Hassan Galadari, MD College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
Joel Gelfand, MD, MSCE University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
Dafna D. Gladman, MD University of Toronto; Krembil Research Institute; Centre for Prognosis Studies in Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Canada
Kenneth Gordon, MD Medical College of Wisconsin, Milwaukee, WI, USA
Chris Griffiths, MB, MD University of Manchester, Manchester, UK
Percio Gulko, MD Icahn School of Medicine at Mount Sinai, New York, NY, USA
Philip Helliwell, MD University of Leeds, Leeds, UK
Sylvia Hsu, MD Baylor College of Medicine Houston, Houston, TX, USA
Abby Jacobson, MS, PA-C Delaware Valley Dermatology Group, LLC, Wilmington, DE, USA
Joseph L. Jorizzo, MD Wake Forest University School of Medicine, Winston-Salem, NC, USA; Weill Cornell Medical College, New York, NY, USA
Arthur Kavanaugh, MD University of California, San Diego, CA, USA
Neil Korman, MD, PhD University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Gerald G. Krueger, MD University of Utah School of Medicine, Salt Lake City, UT, USA
Richard Langley, MD Dalhousie University, Halifax, NS, Canada
Thomas McCormick, PhD Case Western Reserve University, Cleveland, OH, USA
Philip Mease, MD University of Washington, Seattle, WA, USA
Nehal N. Mehta, MD, MSCE National Heart, Lung and Blood Institute, Bethesda, MD, USA
Luigi Naldi, MD Hospital San Bortolo, Vicenza, Italy
Amy Paller, MD Northwestern University, Chicago, IL, USA
Kim Papp, MD, PhD Probity Medical Research, Inc., Ontario, Canada
Lourdes M. Perez-Chada, MD, MMSc International Dermatology Outcome Measures (IDEOM) Research Fellow; Psoriasis and Psoriatic Arthritis Clinical Research Fellow; Brigham and Women's Hospital-Harvard Medical School, Boston, MA, USA
Jörg Prinz, MD Ludwig Maximilian University, Munich, Germany
Ronald Prussick, MD George Washington University, Washington D.C., USA
Lluís Puig, MD, PhD Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Abrar Qureshi, MD, MPH Brown University, Providence, RI, USA
Kristian Reich, MD, PhD Dermatologikum Hamburg, Hamburg, Germany
Cheryl Rosen, MD, FRCPC University of Toronto, Toronto, Canada
David Rosmarin, MD Tufts Medical Center, Boston, MA, USA
Eric Ruderman, MD Northwestern Feinberg School of Medicine, Chicago, IL, USA
Caitriona Ryan, MD, FAAD St. Vincent's University Hospital, Blackrock Clinic, Dublin, Ireland
Enrique Soriano, MD, MS Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Mona Ståhle, MD, PhD Karolinska Institutet, Stockholm, Sweden
Stephen Stone, MD, FAAD SIU Medicine, Springfield, IL, USA
Paul Tebbey, PhD, MBA AbbVie, Chicago, IL, USA
Abby Van Voorhees, MD Eastern Virginia Medical School, Norfolk, VA, USA
John E. Wolf Jr., MA, MD Baylor College of Medicine, Houston, TX, USA
Jashin J. Wu, MD Dermatology Research and Education Foundation, Irvine, CA, USA
Melodie Young, MSN, ANP-C Modern Dermatology and Modern Research Associates, Dallas, TX, USA
  • ProQuest
  • Scopus

Please read the guidelines below, then visit the submission site for Journal of Psoriasis and Psoriatic Arthritis (JPPA) at to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.

Psoriatic disease doesn't discriminate. NPF advocates for improved access to care and meaningful access to treatments for all. JPPA is passionate about supporting diversity, equity, and inclusion in wider society through our publishing activities, which include diversity (ethnic and gender) in our editorial board, peer reviewers, and author base.

Sage Publishing disseminates high-quality research and engaged scholarship globally, and we are committed to diversity and inclusion in publishing. We encourage submissions from a diverse range of authors from across all countries and backgrounds.

Only manuscripts of sufficient quality that meet the aims and scope of the Journal will be reviewed.

As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere. Please see our guidelines on prior publication and note that JPPA may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy. If your paper is accepted, you must include a link on your preprint to the final version of your paper.

This Journal is a member of the Committee on Publication Ethics.

This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

There are no fees payable to submit or publish in this journal.

If you have any questions about publishing with Sage, please visit the Sage Journal Solutions Portal.


  1. What we Publish
    1.1 Aims & Scope
    1.2 Fairness and Equal Opportunity
    1.2.1 Use of inclusive language
    1.2.2 English Language Editing Services
    1.3 Writing Your Paper
    1.4 Article Types
  2. Editorial Policies
  3. Preparing your Manuscript
    3.1 Spacing and Margins
    3.2 Font
    3.3 Figures and Tables
    3.4 Guidelines on Artwork and Other Graphics
  4. Submission Layout
    4.1 Title Page
    4.2 Abstract
    4.3 Key Words
    4.4 Ethics and Consent
    4.4.1 Patient Informed Consent
    4.4.2 Animal Subjects
    4.4.3 Ethical Statement and Informed Consent Template
    4.5 Clinical Trials
    4.6 Abbreviations and Acronyms
    4.7 Brand Names
    4.8 Reference Style
    4.9 Supplemental Material
  5. Research Data and Reporting Guidelines
    5.1 Reporting Methods
    5.2 Reporting Results
  6. Editorial Policies
    6.1 Peer Review Policy
    6.2 Authorship
    6.2.1 Authorship Conditions
    6.2.2 Corresponding Author
    6.3 Acknowledgements
    6.3.1 Third Party Submissions
    6.4 Funding
    6.5 Declaration of Conflicting Interests
  7. Submitting Your Manuscript
    7.1 ORCID
  8. On Acceptance and Publication
    8.1 Sage Production
    8.2 OnlineFirst Publication
    8.3 Promoting Your Article
  9. Further Information
    9.1 Appealing the Publication Decision


1. What we Publish

1.1 Aims & Scope

Before submitting your manuscript to JPPA, please ensure you have read the Aims & Scope.

1.2 Fairness and Equal Opportunity

The National Psoriasis Foundation (NPF) advocates for improved access to care and meaningful access to treatments for all. JPPA supports fairness and equal opportunity in wider society through our publishing activities. There is no discrimination (i.e., age, ethnicity, gender, ability, social class, socioeconomic status, sexual orientation, gender identity, primary spoken language, and geographic region) regarding our editorial board, peer reviewers, and author base.

1.2.1 Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability, or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. Avoid the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability, or health condition unless they are relevant and valid. Refer to the current AMA style guide on race and ethnicity for a complete discussion and examples. These guidelines are meant as a reference to help identify appropriate language but are not exhaustive or definitive. Please see the full AMA Manual of Style for more information.

1.2.2 English Language Editing Services

Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using Sage Language Services. Visit Sage Language Services on our Journal Author Gateway for further information.

1.3 Writing Your Paper

The Sage Author Gateway has some general advice and on how to get published, plus links to further resources.

1.4 Article Types

Manuscripts submitted to the JOURNAL OF PSORIASIS & PSORIATIC ARTHRITIS® should be of general interest to researchers and medical professionals specializing in psoriatic disease research, including comorbidity research, and patient care. Articles, if applicable, must state the type of reporting guideline used within the methods section.

Reports of Original Research (3,000 words)

Original, in-depth clinical and investigative laboratory research papers focused on the fundamental cause and treatment of psoriatic diseases. Requires ethical approval or waiver and detailed patient consent. 

Reviews (3,000 words)

Reviews of literature, clinical trials, or patterns appearing in cases of psoriasis and psoriatic arthritis pertinent to factors such as the cause, diagnosis, prognosis, or therapy of these diseases.

Practical Therapeutics (500 words)

In-depth review of a therapeutic modality or treatment procedure for the treatment of psoriasis or psoriatic arthritis.

Brief Reports (350 words)

Brief clinical observations, reports of studies, or evaluations that are unique to the care of psoriasis or psoriatic arthritis.

Case Reports (1200 words)

Brief individual cases of psoriasis or psoriasis treatment of unusual interest. Requires ethical approval or waiver and detailed patient consent. 

Editorials and Commentaries (500 words)

Brief, provocative, opinionated communications on issues pertinent to the treatment and care of psoriasis or psoriatic arthritis.

Back to top


2. Editorial Policies

JOURNAL OF PSORIASIS & PSORIATIC ARTHRITIS® (JPPA) is a peer-reviewed specialty journal for health care providers and researchers interested in psoriatic disease. It is published by the National Psoriasis Foundation to provide the latest research and practical treatment information about psoriasis and psoriatic arthritis in a concise and easy-to-read format. All medical professionals in the field of psoriatic disease are invited to submit articles for consideration. JOURNAL OF PSORIASIS & PSORIATIC ARTHRITIS® (JPPA) recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE). Manuscripts selected for publication will be published in the print and online version of the Journal.

DISCLAIMER: The National Psoriasis Foundation is a 501(c)(3) lay, patient-driven nonprofit organization with a mission to drive efforts to cure psoriatic disease and improve the lives of those affected. Opinions expressed in this publication are those of the author(s) and do not necessarily reflect the view of the National Psoriasis Foundation, its Board of Directors, or its Medical Board. Only original articles will be considered for publication in JPPA. Please do not submit articles that are being submitted to other journals.

Back to top

3. Preparing your Manuscript

Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS.

3.1 Spacing and Margins

Please line-number all manuscripts. Manuscripts must be typed, double-spaced, with 1-inch or larger margins throughout, including title page, text, references, legends for illustrations, and tables.

3.2 Font

Text should be standard 11-point, Arial font

3.3 Figures and Tables

Manuscripts should contain no more than five total figures and tables. Additional figures and tables may be included in a supplement for web-only publication.

Tables must be editable as they will be styled to match the JPPA brand. Tables created in Microsoft Word or Excel are acceptable editable formats. Preferably, figures should be attached as separate documents, in addition to embedding them into Word documents. Figures should be numbered consecutively (i.e., 1, 2, 3). Multi-part figures must be marked clearly (e.g., 1A, 1B, 1C). Please include file extensions when naming and saving files.

3.4 Guidelines on Artwork and Other Graphics

The National Psoriasis Foundation encourages authors to submit relevant graphic elements, such as photographs, charts, tables, and illustrations. Authors are responsible for seeking permission to republish above-named graphic elements.

Illustrations, pictures, and graphs should be supplied of the highest quality and in an electronic format that helps us to publish your article in the best way possible. Follow the guidelines below to prepare your artwork for the printed issue and the online version.

  • Format: TIFF, JPEG: Common format for pictures (containing no text or graphs). 
    EPS: Preferred format for graphs and line art (retains quality when enlarging/zooming in).
  • Placement: Figures/charts and tables created in MS Word should be included in the main text rather than at the end of the document.
  • Figures and other files created outside Word (i.e., Excel, PowerPoint, JPG, TIFF, EPS, and PDF) should be submitted separately. Please add a placeholder note in the running text (i.e., “[insert Figure 1.]")
  • Resolution: Rasterized based files (i.e., with .tiff or .jpeg extension) require a resolution of at least 300 dpi (dots per inch). Line art should be supplied with a minimum resolution of 800 dpi.
  • Color: Please note that images supplied in color will be published in color online and black and white in print (unless otherwise arranged). Therefore, it is important that you supply images that are comprehensible in black and white as well (i.e., by using color with a distinctive pattern or dotted lines). The captions should reflect this by not using words indicating color.
  • Dimension: Check that the artworks supplied match or exceed the dimensions of the journal. Images cannot be scaled up after origination
  • Fonts: The lettering used in the artwork should not vary too much in size and type (usually sans serif font as a default).

Figures supplied in color will appear in color online regardless of whether these illustrations are reproduced in color in the printed version. For the specifically requested color reproduction in print, you will receive information regarding the costs from Sage after receipt of your accepted article.

For additional guidance on the preparation of illustrations, pictures, and graphs in electronic format, please visit Sage’s Manuscript Submission Guidelines.

Back to top


4. Submission Layout

4.1 Title Page

The title page must include: (1) the title, (2) authors’ names, (3) authors' highest earned academic degrees, (4) institutional affiliations and locations, (5) corresponding author information, (6) summary of funding sources and any authors’ conflicts of interest and, (7) word count, figure count, and number of references. Please note that an additional full disclosure of funding sources and any conflicts of interest are required as separate sections following the Acknowledgements.

4.2 Abstract

All articles must be accompanied by an abstract not exceeding 250 words. The abstract should concisely summarize the major points and purpose of the manuscript and its key conclusions. The abstract should be structured into sections: Background, Objective, Methods, Results, and Conclusion. The abstract should not contain any references.

4.3 Key Words

A list of five to eight key words should appear after the abstract.

4.4 Ethics and Consent

Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki. Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals.

JPPA requires an Ethics and Consent section within the paginated pages of all published articles. Sample text can be found in the associated Ethical Statement and Informed Consent Templates. This information should be included as an end statement in the manuscript. Sample text can be found in the associated Ethical Statement and Informed Consent Templates.

Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number. Should your submission be exempt, or receive a waiver, rationale must be provided. The editor may require supporting approval or consent documentation in order to confirm ethical conduct of the reported research.

Sample text can be found in the associated Ethical Statement and Informed Consent Templates.

4.4.1 Patient Informed Consent

For research articles authors are required to state in the Ethics and Consent section whether participants provided informed consent and whether the consent was written or verbal.

For individual cases, or case series, a statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

The written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file. Do not submit the patient’s written informed consent with your article, as this breaches the patient’s confidentiality.

Patients must not be identified by name or initials; numbers should be used. No other information, including clinical photos or family trees from which a patient could be identified, is permitted unless express written permission from the patient or family is provided at the time of manuscript submission. 

Sample text can be found in the associated Ethical Statement and Informed Consent Template. Do not submit the patient’s written informed consent with your article, as this breaches the patient’s confidentiality. Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

4.4.2 Animal Subjects

All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.

Sample text can be found in the associated Ethical Statement and Informed Consent Template.

4.4.3 Ethical Statement and Informed Consent Template

The following statements provide templates for the distinct types of ethical statements required for journal articles. Ethical statements are required for original research and case studies/series and may be requested for other types of articles at the discretion of the editors.

Authors may use these as a guide when drafting their manuscripts. Please note there are many different types of statements and situations, so several examples are provided, but may not cover all cases. This information should be included as an end statement and may also be included in the methods section as well.

Ethics and Institutional Review Board (IRB) Templates

1. Ethical approval for this study/case/case series was obtained from [name of ethics committee or IRB (include approval number/id)].

2. Ethical approval for this study was waived by [name of ethics committee or IRB] because [reason for waiver].

3. Our institution does not require ethics approval for reporting [type of research, e.g., case study].

4. The IRB determined that the protocol is considered exempt because [reason] on [date].

5. This research did not require IRB approval/ethical approval because [reason].

Informed Consent

1. Written informed consent was obtained for anonymized patient information to be published in this article.

2. Verbal informed consent was obtained for anonymized patient information to be published in this article.

3. Informed consent for patient information to be published in this article was not obtained because [reason].

Animal Welfare

1. The present study followed international, national, and/or institutional guidelines for humane animal treatment and complied with relevant legislation from [name of IRB or national/international guideline].

2. Guidelines for humane animal treatment did not apply to the present study because [reason].

4.5 Clinical Trials

JPPA conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

4.6 Abbreviations and Acronyms

Only standard abbreviations are to be used. Consult the Manual of Style by the American Medical Association. Abbreviations in the title are not acceptable, and they should be avoided in the abstract.

A laboratory or chemical term or a disease process must be spelled out on first reference, with the acronym or abbreviation following in parentheses. The abbreviation or acronym should be used thereafter except in headlines.

  • Weights and measurements must be expressed in metric units. Temperatures must be expressed in degrees centigrade.

4.7 Brand names

Brand names of drugs and devices may not be used in the title of the paper. They may appear only once in the paper and should be placed in parentheses along with their manufacturer and the manufacturer's location following the first mention of the generic name in the text. Thereafter, only generic names should be used throughout the article.

4.8 Reference Style

JPPA adheres to the AMA reference style. Please review the AMA guidelines to ensure your manuscript conforms to this reference style.

Manuscripts should contain no more than 75 references. Additional references may be included in a supplement for web-only publication.

Limit references to those that are essential or most relevant. Number references in the order they appear in the text. In text, tables, and legends, indicate references with superscript Arabic numerals. When listing references, abbreviate names of journals according to Index Medicus. Please include full page range. Questions about references should be addressed to

List the first six authors; when there are more than six authors, list the first three authors followed by et al. Do not list only the first author followed by et al.

Additional resources for formatting references can be found at:

4.9 Supplemental Material

This journal can host additional materials online (e.g., datasets, podcasts, videos, images) alongside the full text of the article. These will be subjected to peer-review alongside the article. For more information, please refer to the guidelines on submitting supplemental files

Back to top

5. Research Data and Reporting Guidelines

The journal is committed to facilitating openness, transparency, and reproducibility of research, and has the following research data sharing policy. 

Subject to appropriate ethical and legal considerations, authors are encouraged to:

  • share your research data in a relevant public data repository
  • include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
  • cite this data in your research

5.1 Reporting Methods

Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to judge its appropriateness for the study and to verify the reported results. When possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Avoid relying solely on statistical hypothesis testing, such as P values, which fail to convey essential information about effect size and precision of estimates. References for the design of the study and statistical methods should be to standard works when possible (with pages stated). Define statistical terms, abbreviations, and most symbols. Specify the statistical software package(s) and versions used. Distinguish prespecified from exploratory analyses, including subgroup analyses.

  • Describe the type of study, e.g., randomized clinical trial phase III, pilot, case–control, meta-analysis etc.
  • Indicate the aim of the statistical analysis (primary objective, secondary objective, exploratory or ancillary analysis).
  • Describe the statistical methods in the order in which are used in the results.
  • Make it clear which statistical test was used for which variable.
  • State if any assumptions were checked and how.
  • Describe how missing data was handled (if data is missing).
  • Describe any planned sensitivity or subgroup analyses.
  • If relevant, include a sample-size calculation, with sufficient detail so it can be verified, and report the minimal clinically significant difference (if possible).
  • Report the alpha-level (one or two sided) and the statistical package.
  • Describe with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results. For more details about reporting standards, please see the ICJME recommendations.

5.2 Reporting Results

  • Present in the same order of importance as described in the methods.
  • Include effect sizes and their 95% confidence intervals with the appropriate degree of precision, in addition to P-values. Please read this editorial and accompanying paper on how to report confidence intervals.
  • Adjusted data for multiple testing.
  • Include both absolute and relative measures.
  • Provide enough detail that the results can be incorporated into other analyses; for example, in future meta-analytical studies if reporting a continuous outcome, provide mean (standard deviation), while for categorical outcomes when reporting relative summary statistics, please include the frequency of the outcome (numerator) over the total sample observed (denominator). In addition to these recommendations, all applicable general and study-specific SAMPL guidelines should be followed. 

The relevant EQUATOR NETWORK reporting guidelines should be followed depending on the type of study.

  • CONSORT: Evidence-based, 25-item checklist containing the minimum recommendations for reporting Randomized Clinical Trials (RCTs).
  • STROBE: Cohort, case-control, and cross-sectional studies.
  • PRISMA: Reporting systematic reviews and meta-analyses.
  • CARE: Evidence-based, minimum recommendations for case reports. The CARE guidelines provide early signs of what may work for patients.
  • ARRIVE: For reporting animal research and peer-reviewers of animal research studies.
  • SQUIRE: For reports that descrie system level work to improve the quality, safety, and value of healthcare, and used methods to establish that observed outcomes were due to the intervention(s).


Randomized Controlled Trials

Authors of randomized controlled trials must follow the guidelines presented in the CONSORT statement, and submit a completed CONSORT manuscript checklist with their manuscript. A copy of the "CONSORT Checklist for Authors Submitting Reports of Randomized Controlled Trials" may be downloaded from the JAAD Web site. Similar guidelines for authors of observational and epidemiologic studies are included in the STROBE statement and the related RECORD checklist, for observational comparative effectiveness studies in the GRACE principles, and for studies of diagnostic accuracy in the STARD statement.

Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

For more information, including FAQs please visit the Sage Research Data policy pages.

Back to top

6. Editorial Policies

6.1 Peer Review Policy

JPPA operates a conventional single-anonymized reviewing policy in which the reviewer’s name is always concealed from the submitting author.

The editorial staff will review the manuscript and, if it meets JPPA’s editorial standards and submission criteria, will send it to at least two reviewers. Reviewers are experts in their fields who can provide an objective assessment of the manuscript. Reviewers will not be assigned to a paper if:

  • The reviewer is based at the same institution as any of the co-authors.
  • The reviewer is based on the funding body of the paper.
  • The author has recommended the reviewer.
  • The reviewer has provided a personal email address (e.g., Gmail/Yahoo/Hotmail) and an institutional email account cannot be found after performing a basic Google search (name, department, and institution).

Reviewers will pay particular attention to scientific accuracy, adherence to reporting guidelines, relevance, novelty, importance, and appropriate style of the submission. Decisions on manuscripts will be made as rapidly as possible. 

Some degree of manuscript revision should be expected and regarded as constructive. A request to submit a revised manuscript does not guarantee that it will be accepted; rather this means the submission will be reconsidered after additional peer review.

The Editor or members of the Editorial Board may occasionally submit their own manuscripts for publication in the Journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will not be involved in the decision-making process.

The Editors also require the reviewer to disclose any competing interests or conflicts of interest that might interfere with their objectivity (or to recuse oneself from acting as a reviewer). The Editors and members of the editorial staff have registered their competing interests with the National Psoriasis Foundation. The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions.

JPPA is committed to delivering high quality, peer-review for your paper, and thus has partnered with Web of Science (previously Publons). Web of Science is a third-party service that seeks to track, verify, and give credit for peer review. Reviewers for JPPA can opt in to Web of Science to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of the review is not published on the site. For more information visit the Web of Science website.

6.2 Authorship

6.2.1 Authorship Conditions

Papers should only be submitted for consideration once consent is given by all contributing authors. JPPA adheres to the authorship guidelines outlined in the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals.

In summary, each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section.

Authors should meet all the following ICMJE recommendations:

1. Made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data; AND

2. Drafted the article or revised it critically for important intellectual content; AND

3. Final approval of the version to be published. AND

4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

6.2.2 Corresponding Author

All authors should identify one corresponding author who accepts primary responsibility for the submission, peer-review, and publication process. The JPPA editorial staff will only communicate with the corresponding author, however, other authors can be designated to receive relevant emails.

Upon acceptance of manuscript, the corresponding author must submit a License to Publish form. This contributor form will be emailed to the address on file. Additionally, the corresponding author’s complete address, telephone and fax numbers, and e-mail address must be provided on the title page.

Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.

6.3 Acknowledgements

All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

6.3.1 Third party submissions

For individuals who have provided writing assistance and/or submit a manuscript on behalf of the author(s) but who do not qualify as authors, a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:

  • Disclose this type of editorial assistance – including the individual’s name, company, and level of input
  • Identify any entities that paid for this assistance
  • Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g., conflicting interests, funding, etc.

It is not necessary to disclose the use of language polishing services.

Where appropriate, Sage reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.

6.4 Funding

The Journal requires all authors to acknowledge their funding in a consistent fashion under a separate heading. It should appear under the heading ‘Funding’ after any Acknowledgments and Declaration of conflicting interests, and before Notes and References. Please visit the Funding Acknowledgements page on the Sage Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

6.5 Declaration of Conflicting Interests

JPPA requires a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles. 

The Journal requires all authors to acknowledge their institutional or corporate affiliations and funding sources. These include, but are not limited to, employment, royalties, consulting arrangements with a commercial entity, stock or other equity ownership, stock options, patent licensing arrangements, payments for conducting or publicizing a product or study, or consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product.

Please ensure that a "Declaration of Conflicting Interests" statement is included at the end of your manuscript, after any acknowledgements and prior to the references. Please ensure that each author is represented in the statement. If no conflict exists, please state that "The Author(s) declare(s) that there are no conflicts of interest." It is acceptable to indicate authors by their initials.

For guidance on conflict-of-interest statements, please see the ICMJE recommendations here.

Back to top

 7. Submitting Your Manuscript

JPPA is hosted on Sage Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit to login and submit your article online.

IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you reviewed or wrote for the journal in the past year, you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.


As part of our commitment to ensuring an ethical, transparent, and fair peer review process, Sage is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.

The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID ID, you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms by following the below steps:

Click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID ID will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID ID is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

If you do not already have an ORCID ID, please follow this link to create one or visit our ORCID homepage to learn more. 

Back to top


8. On Acceptance and Publication

8.1 Sage Production

Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be made available to the corresponding author via our editing portal Sage Edit or by email, and corrections should be made directly or notified to us promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence, and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate.

8.2 OnlineFirst Publication

OnlineFirst allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the Sage Journals help page for more details, including how to cite OnlineFirst articles.

Sage provides authors with online access to their final article.

8.3 Promoting Your Article

Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The Sage Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.

For information and guidance on how to make your article more discoverable, visit our Gateway page on How to Help Readers Find Your Article Online.

Back to top

9. Further Information

Any correspondence, queries, or additional requests for information on the manuscript submission process should be sent to the JPPA editorial office:

9.1 Appealing the Publication Decision

Editors have very broad discretion in determining whether an article is an appropriate fit for their journal. Many manuscripts are declined with a very general statement of the rejection decision. These decisions are not eligible for formal appeal unless the author believes the decision to reject the manuscript was based on an error in the review of the article, in which case the author may appeal the decision by providing the Editor with a detailed written description of the error they believe occurred.

If an author believes the decision regarding their manuscript was affected by a publication ethics breach, the author may contact the publisher with a detailed written description of their concern, and information supporting the concern, at

For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the Sage Author Gateway.

Back to top

Individual Subscription, E-access

Individual Subscription, Print Only

Individual Subscription, Combined (Print & E-access)

Institutional Subscription, E-access

Institutional Backfile Purchase, E-access (Content through 1998)

Institutional Subscription & Backfile Lease, E-access Plus Backfile (All Online Content)

Institutional Subscription, Print Only

Institutional Subscription, Combined (Print & E-access)

Institutional Subscription & Backfile Lease, Combined Plus Backfile (Current Volume Print & All Online Content)

Individual, Single Print Issue

Institutional, Single Print Issue